Echinocandins: A wealth of choice - How clinically different are they?

Current Opinion in Infectious Diseases

Volumn 21, Issue 4, 2008, Pages 426-432

  Zaas, Aimee K ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antifungal therapy; Candidiasis; Echinocandin

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CARBAMAZEPINE; CASPOFUNGIN; CYCLOSPORIN; DEXAMETHASONE; EFAVIRENZ; FLUCONAZOLE; METRONIDAZOLE; MICAFUNGIN; NEVIRAPINE; NIFEDIPINE; PHENYTOIN; RAPAMYCIN; RIFAMPICIN; TACROLIMUS; ANTIFUNGAL AGENT; ECHINOCANDIN; TRIAZOLE DERIVATIVE;

ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ASPERGILLOSIS; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA GUILLIERMONDII; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDIASIS; CLINICAL TRIAL; DRUG CHOICE; DRUG DEGRADATION; DRUG HYDROLYSIS; DRUG INDICATION; ESOPHAGUS CANDIDIASIS; FEBRILE NEUTROPENIA; HUMAN; MINIMUM INHIBITORY CONCENTRATION; OUTCOME ASSESSMENT; REVIEW; THRUSH; CHEMOPROPHYLAXIS; DRUG COMBINATION; DRUG EFFECT; FUNGUS;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; CHEMOPREVENTION; DRUG THERAPY, COMBINATION; ECHINOCANDINS; FUNGI; HUMANS; TRIAZOLES;

EID: 49049111363     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e328307c79c     Document Type: Review

References (62)

1. Cornillet A, Camus C, Nimubona S, et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis 2006; 43:577-584.
2. Husain S, Alexander BD, Munoz P, et al. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis 2003; 37:221-229.
3. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20:133-163. The article represents the most current and comprehensive review of invasive candidiasis available.
4. Upton A, Marr KA. Emergence of opportunistic mould infections in the hematopoietic stem cell transplant patient. Curr Infect Dis Rep 2006; 8:434-441.
5. Zaas AK, Alexander BD. Echinocandins: role in antifungal therapy, 2005. Expert Opin Pharmacother 2005; 6:1657-1668.
6. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38:161-189.
7. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45:883-893. A randomized, double-blinded prospective clinical trial of approximately 600 patients with invasive candidiasis established the equivalence of micafungin and caspofungin for the treatment of invasive candidiasis, as well as the 100 mg i.v. q.d. dose for micafungin.
8. Cornely OA, Lasso M, Betts R, et al. Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrob Chemother 2007; 60:363-369.
9. Hiemenz J, Cagnoni P, Simpson D, et al. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother 2005; 49:1331-1336.
10. Sirohi B, Powles RL, Chopra R, et al. A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 38:47-51.
11. Caillot D, Thiebaut A, Herbrecht R, et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer 2007; 110:2740-2746.
12. Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39:797-802.
13. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362:1142-1151.
14. Diekema DJ, Petroelje B, Messer SA, et al. Activities of available and investigational antifungal agents against rhodotorula species. J Clin Microbiol 2005; 43:476-478.
15. Merck: Cancidas (Caspofungin sodium). Package Insert 2002.
16. Pharmaceuticals A. Mycamine (micafungin sodium). Package Insert 2005.
17. Pfizer: Eraxis (anidulafungin). Package Insert 2006.
18. de la Torre P, Reboli AC. Anidulafungin: a new echinocandin for candidal infections. Expert Rev Anti Infect Ther 2007; 5:45-52.
19. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103:1527-1533.
20. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347:2020-2029.
21. Betts R, Glasmacher A, Maertens J, et al. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients. Cancer 2006; 106:466-473.
22. Krause DS, Reinhardt J, Vazquez JA, et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother 2004; 48:2021-2024.
23. Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369:1519-1527. The trial led to the US-FDA approval for micafungin for the treatment of invasive candidiasis.
24. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 2005; 24:654-661.
25. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356:2472-2482. The trial led to the US-FDA approval of anidulafungin for the treatment of invasive candidiasis. Notably, anidulafungin was statistically superior to fluconazole at the end of intravenous therapy as treatment was successful in 75.6% of patients treated with anidulafungin, as compared with 60.2% of those treated with fluconazole [difference, 15.4 percentage points; 95% confidence interval (CI), 3.9-27.0].
26. de Wet N, Llanos-Cuentas A, Suleiman J, et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004; 39:842-849.
27. Krause DS, Simjee AE, van Rensburg C, et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004; 39:770-775.
28. Villanueva A, Arathoon EG, Gotuzzo E, et al. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001; 33:1529-1535.
29. Benjamin DK Jr, Driscoll T, Seibel NL, et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother 2006; 50:632-638.
30. Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Anti-microb Agents Chemother 2005; 49:3317-3324.
31. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351:1391-1402.
32. van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39:1407-1416.
33. Denning DW, Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006; 53:337-349.
34. Kartsonis NA, Saah AJ, Joy Lipka C, et al. Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. J Infect 2005; 50:196-205.
35. Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003; 98:292-299.
36. Maertens J, Glasmacher A, Herbrecht R, et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006; 107:2888-2897.
37. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39:1563-1571.
38. Singh N, Limaye AP, Forrest G, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006; 81:320-326.
39. Arathoon EG, Gotuzzo E, Noriega LM, et al. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 2002; 46:451-457.
40. Kartsonis N, DiNubile MJ, Bartizal K, et al. Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. J Acquir Immune Defic Syndr 2002; 31:183-187.
41. Villanueva A, Gotuzzo E, Arathoon EG, et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002; 113:294-299.
42. Pettengell K, Mynhardt J, Kluyts T, et al. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment Pharmacol Ther 2004; 20:475-481.
43. Watabe E, Nakai T, Matsumoto S, et al. Killing activity of micafungin against Aspergillus fumigatus hyphae assessed by specific fluorescent staining for cell viability. Antimicrob Agents Chemother 2003; 47:1995-1998.
44. Safdar A, Rodriguez G, Rolston KV, et al. High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 39:157-164.
45. Walsh TJ, Adamson PC, Seibel NL, et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005; 49:4536-4545.
46. Odio CM, Araya R, Pinto LE, et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J 2004; 23:1093-1097.
47. Smith PB, Steinbach WJ, Cotten CM, et al. Caspofungin for the treatment of azoleresistant candidemia in a premature infant. J Perinatol 2007;27:127-129.
48. Heresi GP, Gerstmann DR, Reed MD, et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J 2006; 25:1110-1115.
49. Hope WW, Mickiene D, Petraitis V, et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis 2008; 197:163-171. An elegant and novel study evaluating the pharmacokinetics of micafungin in a rabbit model of neonatal candidal meningitis.
50. Pfaller MA, Boyken L, Hollis RJ, et al. Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods. J Clin Microbiol 2006; 44:3533-3538.
51. Pfaller MLB, Hollis RJ, Kroeger J, et al. In vitro susceptibility of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance [abstract no. M-552]. In: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, Illinois: ASM Press; 2007.
52. Brielmaier BD, Casabar E, Kurtzeborn CM, et al. Early clinical experience with anidulafungin at a large tertiary care medical center. Pharmacotherapy 2008; 28:64-73.
53. Cheung C, Guo Y, Gialanella P, et al. Development of candidemia on caspofungin therapy: a case report. Infection 2006; 34:345-348.
54. Forrest GN, Weekes E, Johnson JK. Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J Infect 2008; 56:126-129.
55. Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008; 46:150-156.
56. Pasquale T, Tomada JR, Ghannoun M, et al. Emergence of Candida tropicalis resistant to caspofungin. J Antimicrob Chemother 2008; 61:219.
57. Baixench MT, Aoun N, Desnos-Ollivier M, et al. Acquired resistance to echinocandins in Candida albicans: case report and review. J Antimicrob Chemother 2007; 59:1076-1083.
58. Balashov SV, Park S, Perlin DS. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother 2006; 50:2058-2063.
59. Hakki M, Staab JF, Marr KA. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Chemother 2006; 50:2522-2524.
60. Stevens DA, Ichinomiya M, Koshi Y, et al. Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin. Antimicrob Agents Chemother 2006; 50:3160-3161.
61. Wiederhold NP, Kontoyiannis DP, Prince RA, et al. Attenuation of the activity of caspofungin at high concentrations against Candida albicans: possible role of cell wall integrity and calcineurin pathways. Antimicrob Agents Chemother 2005; 49:5146-5148.
62. Chamilos G, Lewis RE, Albert N, et al. Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences. Antimicrob Agents Chemother 2007; 51:2257-2259.